Stockscreener 앱 받기
43.92
2.86%
1.22
시간 외 거래:
44.50
0.58
+1.32%
Exelixis Inc 주식(EXEL)의 최신 뉴스
Why Exelixis Inc. (EX9) stock could be next leader2025 Price Action Summary & Free High Return Stock Watch Alerts - mfd.ru
Illinois Municipal Retirement Fund Boosts Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Aug Wrap: What is the earnings history of Exelixis IncWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Understanding the Setup: (EXEL) and Scalable Risk - Stock Traders Daily
Assetmark Inc. Has $131.99 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (EXEL) Q4 2025 Earnings Call Transcript - AOL.com
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright - Investing.com Nigeria
Exelixis (EXEL) Receives a Buy from Stephens - The Globe and Mail
RBC Capital Sticks to Its Hold Rating for Exelixis (EXEL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and OrganiGram Holdings (OGI) - The Globe and Mail
Exelixis Reports Solid Earnings-Are New Highs Back on the Table? - Finviz
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? - MarketBeat
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright By Investing.com - Investing.com South Africa
Westover Capital Advisors LLC Grows Stake in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by LSV Asset Management - MarketBeat
EXEL: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
A Glimpse Into The Expert Outlook On Exelixis Through 10 Analysts - Benzinga
Can Exelixis Inc. stock outperform in a bear marketInsider Selling & AI Driven Stock Movement Reports - mfd.ru
FDA Review Of Zanzalintinib Combo Highlights Exelixis Valuation Gap - Yahoo Finance
Exelixis (NASDAQ:EXEL) Price Target Raised to $46.00 - MarketBeat
EXEL: Stifel Raises Price Target to $44 and Maintains Hold Ratin - GuruFocus
Exelixis (NASDAQ:EXEL) Price Target Raised to $35.00 - MarketBeat
Citizens maintains Exelixis stock rating on promising cancer treatment data By Investing.com - Investing.com Canada
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus - Yahoo Finance
RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating - marketscreener.com
Citizens maintains Exelixis stock rating on promising cancer treatment data - Investing.com
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript - Insider Monkey
Essex Investment Management Co. LLC Raises Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - GuruFocus
Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Exelixis Q4 2025 Earnings Call Transcript - MarketBeat
Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch - MSN
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics - sharewise.com
Exelixis (EXEL) Reports Strong Q4 2025 Earnings with Robust Grow - GuruFocus
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion By Investing.com - Investing.com South Africa
Exelixis Q4 Earnings Call Highlights - Yahoo Finance
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Upda - PharmiWeb.com
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com
Earnings call transcript: Exelixis Q4 2025 reports EPS beat, stock dips - Investing.com India
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue - ChartMill
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Exelixis: Q4 Earnings Snapshot - KVUE
Why Exelixis (EXEL) is one of the best healthcare stocks under $50 to invest in - MSN
EXEL: Amended Ipsen deal grants exclusive cabozantinib rights outside U.S./Japan, $200M upfront, royalties - TradingView
EXELIXIS, INC. SEC 10-K Report - TradingView
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B$2.63B, vs. FactSet Est of $2.62B - marketscreener.com
Exelixis, Inc. Profit Climbs In Q4 - Nasdaq
Exelixis (NASDAQ:EXEL) Posts Quarterly Earnings Results, Beats Expectations By $0.20 EPS - MarketBeat
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - The Joplin Globe
Exelixis earnings on deck: Can zanzalintinib justify valuation? - Investing.com
1.12%
0.87%
자본화:
|
볼륨(24시간):